Imidazopyridyl compounds as aldosterone synthase inhibitors

详细信息    查看全文

• 作者：Brent R. Whitehead^a ; ^{brent.whitehead@merck.com} ; Michael M.-C. Lo^a ; Amjad Ali^a ; Min K. Park^a ; Scott B. Hoyt^a ; Yusheng Xiong^a ; Jiaqiang Cai^b ; Emma Carswell^b ; Andrew Cooke^b ; John MacLean^b ; Paul Ratcliffe^b ; John Robinson^b ; D. Jonathan Bennett^b ; Joseph A. Clemas^a ; Tom Wisniewski^a ; Mary Struthers^a ; Doris Cully^a ; Douglas J. MacNeil^a
• 关键词：Aldosterone ; CYP11B2 ; Hypertension ; Imidazopyridine ; Heart failure
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：27
• 期：2
• 页码：143-146
• 全文大小：396 K
• 卷排序：27

文摘

The inhibition of aldosterone synthase (CYP11B2) may be an effective treatment of hypertension and heart failure, among other ailments. Previously reported benzimidazole CYP11B2 inhibitors led the way for bioisosteric imidazopyridines that are both potent and selective over CYP11B1.